0000000000529064

AUTHOR

A Simonato

showing 8 related works from this author

Analisi delle varianti rare del carcinoma a cellule uroteliali della vescica nei Pazienti sottoposti a cistectomia radicale: impatto sulla prognosi.

2013

Tumore vescicale cistectomia istologiaSettore MED/24 - Urologia
researchProduct

Telehealth in Urology: A Systematic Review of the Literature. How Much Can Telemedicine Be Useful During and After the COVID-19 Pandemic?

2020

Context Coronavirus disease 2019 (COVID-19) pandemic has caused increased interest in the application of telehealth to provide care without exposing patients and physicians to the risk of contagion. The urological literature on the topic is sparse. Objective To perform a systematic review of the literature and evaluate all the available studies on urological applications of telehealth. Evidence acquisition After registration on PROSPERO, we searched PubMed and Scopus databases to collect any kind of studies evaluating any telehealth interventions in any urological conditions. The National Toxicology Program/Office of Health Assessment and Translation Risk of Bias Rating Tool for Human and A…

Coronavirus; COVID-19; E-health; Severe acute respiratory syndrome coronavirus 2; Telehealth; Telemedicinemedicine.medical_specialtyTelemedicineTelemedicine.UrologyUrinary systemCoronaviru030232 urology & nephrologyPsychological interventionUrinary incontinenceContext (language use)TelehealthArticleCOVID-19; Coronavirus; E-health; Severe acute respiratory syndrome coronavirus 2; Telehealth; Telemedicinelaw.invention03 medical and health sciences0302 clinical medicineRandomized controlled triallawHealth caremedicineSevere acute respiratory syndrome coronavirus 2Intensive care medicineE-healthCOVID-19; Coronavirus; E-health; Severe acute respiratory syndrome coronavirus 2; Telehealth; Telemedicine.business.industryCOVID-19COVID-19 Coronavirus E-health Severe acute respiratory syndrome coronavirus 2 Telehealth Telemedicine.TelemedicineCoronavirusTelehealth030220 oncology & carcinogenesismedicine.symptombusinessCoronavirus COVID-19 E-health Severe acute respiratory syndrome coronavirus 2 Telehealth TelemedicineEuropean Urology
researchProduct

Erratum: Validation of the 2009 TNM version in a large multi-institutional cohort of patients treated for renal cell carcinoma: Are further improveme…

2011

A new edition of the TNM was recently released that includes modifications for the staging system of kidney cancers. Specifically, T2 cancers were subclassified into T2a and T2b (10 cm), tumors with renal vein involvement or perinephric fat involvement were classified as T3a cancers, and those with adrenal involvement were classified as T4 cancers. OBJECTIVE: Our aim was to validate the recently released edition of the TNM staging system for primary tumor classification in kidney cancer. DESIGN, SETTING, AND PARTICIPANTS: Our multicenter retrospective study consisted of 5339 patients treated in 16 academic Italian centers. INTERVENTION: Patients underwent either radical or partial nephrecto…

Oncologymedicine.medical_specialtyCorrigendum to ‘‘Validation of the 2009 TNM Version in a Largebusiness.industryUrologyUrologyRenal Cell Carcinomamedicine.diseaseTNMTNM; Renal Cell CarcinomaRenal cell carcinomaInternal medicineCohortmedicinebusinesserratum error priority journal
researchProduct

Outcomes after perioperative SARS-CoV-2 infection in patients with proximal femoral fractures: an international cohort study

2021

ObjectivesStudies have demonstrated high rates of mortality in people with proximal femoral fracture and SARS-CoV-2, but there is limited published data on the factors that influence mortality for clinicians to make informed treatment decisions. This study aims to report the 30-day mortality associated with perioperative infection of patients undergoing surgery for proximal femoral fractures and to examine the factors that influence mortality in a multivariate analysis.SettingProspective, international, multicentre, observational cohort study.ParticipantsPatients undergoing any operation for a proximal femoral fracture from 1 February to 30 April 2020 and with perioperative SARS-CoV-2 infec…

Malemedicine.medical_specialty2474Multivariate analysisMORTALITY-RATEShipSURGERYSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)MULTICENTERCOVIDSurg Collaborative1117 Public Health and Health ServicesCohort StudiesMedicine General & InternalInternal medicineGeneral & Internal MedicinemedicineDementiaHumans1506Prospective StudiesAged 80 and overCOMPLICATIONSScience & TechnologyHIP-FRACTURESbusiness.industryHip FracturesSARS-CoV-2RCOVID-191103 Clinical SciencesGeneral MedicineFemoral fracturePerioperativemedicine.diseaseHeart failuretrauma managementMedicineSurgery1737businessLife Sciences & BiomedicineFemoral FracturesKidney diseaseCohort study1199 Other Medical and Health SciencesBMJ Open
researchProduct

Prognostic factors in a large multi-institutional series of papillary renal cell carcinoma.

2011

OBJECTIVES To investigate cancer-related outcomes and prognostic factors of papillary renal cell carcinoma (pRCC) in a large multicentre data set. Oncological outcome and prognostic factors of pRCC have been limitedly evaluated in comparison with the most common RCC subtype, clear cell RCC. PATIENTS AND METHODS From a multicentre retrospective database, including 5463 patients who were surgically treated for RCC at 16 Italian academic centres between 1995 and 2007, 577 patients with pRCC were identified. Univariable and multivariable Cox regression models were performed to identify prognostic factors predictive of recurrence-free survival (RFS) and cancer-specific survival (CSS) after surge…

Malerenal cell carcinomaTime FactorsPapillary renal cell carcinoma; Prognostic factorsPrognosiFEATURESkidney cancer; papillaryrenal cell carcinoma; papillary adenocarcinoma; prognostic factorspapillary renal cell carcinomaNephrectomyCLASSIFICATIONFollow-Up Studiecancer-specific survivalpapillaryRisk FactorsRetrospective StudieCause of DeathPrevalenceHumansrecurrence-free survivalprognostic factorCarcinoma Renal CellTYPE-1Proportional Hazards ModelsRetrospective StudiesNeoplasm StagingAcademic Medical Centerspapillary adenocarcinomaRisk Factorkidney cancerKidney Neoplasmprognostic factorsMiddle AgedPrognosisTUMORSKidney NeoplasmsHISTOLOGIC SUBTYPESPrognostic factors in a large multi-institutional series of papillary renal cell carcinoma.Survival RateAcademic Medical CenterItalySURVIVALProportional Hazards ModelFemaleprognostic factors; papillary renal cell carcinoma; recurrence-free survival; cancer-specific survivalFollow-Up StudiesHuman
researchProduct

Features Associated with Recurrence Beyond 5 Years After Nephrectomy and Nephron-Sparing Surgery for Renal Cell Carcinoma: Development and Internal V…

2014

Background: Approximately 10-20% of recurrences in patients treated with nephrectomy for renal cell carcinoma (RCC) develop beyond 5 yr after surgery (late recurrence). Objective: To determine features associated with late recurrence. Design, setting, and participants: A total of 5009 patients from a multicenter database comprising 13 107 RCC patients treated surgically had a minimum recurrence-free survival of 60 mo (median follow-up [FU]: 105 mo [range: 78-135]); at last FU, 4699 were disease free (median FU: 103 mo [range: 78-134]), and 310 patients (6.2%) experienced disease recurrence (median FU: 120 mo [range: 93-149]). Interventions: Patients underwent radical nephrectomy or nephron-…

MaleTime FactorsDatabases FactualLymphovascular invasionmedicine.medical_treatmentPredictive Value of Testcomputer.software_genreNephrectomyRisk modelDecision Support TechniqueRisk FactorsRetrospective StudieRenal cell carcinomaOdds Ratiolate recurrencenephrectomyMedicineMultivariate AnalysiFramingham Risk ScoreDatabaseKidney Neoplasmrenal carcinomaPrognostic parametersMiddle AgedNephrectomyKidney NeoplasmsTreatment OutcomeLymphatic MetastasisFemaleRadiologyNephron sparing surgeryPrognostic parameterHumanmedicine.medical_specialtyrenal cell carcinomarecurrenceLogistic ModelTime FactorUrologyReproducibility of ResultLate recurrencecancer-specific mortalityrisk scoreRisk AssessmentDisease-Free SurvivalDecision Support Techniquescancer-specific mortality; late recurrence; nephrectomy; prognostic parameters; renal cell carcinoma; risk scorePredictive Value of TestsLate RecurrenceHumansInternal validationCarcinoma Renal CellProportional Hazards ModelsRetrospective StudiesAgedNeoplasm StagingChi-Square Distributionbusiness.industryProportional hazards modelRisk Factorrenal cell carcinoma; recurrence; Cancer-specific mortality; Late recurrence; Nephrectomy; Prognostic parameters; Risk scoreCancer-specific mortalityReproducibility of ResultsLymphatic MetastasiRetrospective cohort studyOdds ratioprognostic parametersmedicine.diseaseConfidence intervalLogistic ModelsMultivariate AnalysisProportional Hazards ModelRisk scoreNeoplasm GradingNeoplasm Recurrence LocalbusinesscomputerCancer-specific mortality; Late recurrence; Nephrectomy; Prognostic parameters; Renal cell carcinoma; Risk score
researchProduct

Validation of the 2009 TNM Version in a Large Multi-Institutional Cohort of Patients Treated for Renal Cell Carcinoma: Are Further Improvements Neede…

2010

Background: A new edition of the TNM was recently released that includes modifications for the staging system of kidney cancers. Specifically, T2 cancers were subclassified into T2a and T2b ( 10 cm), tumors with renal vein involvement or perinephric fat involvement were classified as T3a cancers, and those with adrenal involvement were classified as T4 cancers. Objective: Our aim was to validate the recently released edition of the TNM staging system for primary tumor classification in kidney cancer. Design, setting, and participants: Our multicenter retrospective study consisted of 5339 patients treated in 16 academic Italian centers. Intervention: Patients underwent either radical or part…

MaleNephrologyOncologyIMPACTmedicine.medical_treatmentValidation of the 2009 TNM version in a large multi-institutional cohort of patients treated for renal cell carcinoma: are further improvements needed?Kidney neoplasm; Nephrectomy; Renal cell carcinoma; TNM; UrologyNephrectomyTNMCohort StudiesTNM; renal cell carcinomarenal cell carcinoma; staging systemPROPOSALKidney neoplasm; Nephrectomy; Renal cell carcinoma; TNMRenal cell carcinomaPRIMARY TUMOR CLASSIFICATIONstaging systemNEPHRECTOMYRECLASSIFICATIONkidney cancerRADICAL NEPHRECTOMYMiddle AgedKidney neoplasmPrimary tumorKidney NeoplasmsNephrectomyREVISIONclassificationCohortCUTOFFKidney neoplasm; Nephrectomy; Renal cell carcinoma; TNM; Aged; Carcinoma Renal Cell; Cohort Studies; Female; Humans; Kidney Neoplasms; Male; Middle Aged; Neoplasm Staging; Retrospective StudiesFemalekidney neoplasmHumanrenal cell carcinomamedicine.medical_specialtyUrologyTNM staging systemSTRATIFICATIONInternal medicinemedicineHumansCarcinoma Renal CellAgedNeoplasm StagingRetrospective Studiesbusiness.industrykidney neoplasm; renal cell carcinoma; TNM; NEPHRECTOMYCarcinomaRenal CellRetrospective cohort studymedicine.diseaseSurgerySIZECohort StudiebusinessKidney cancerKidney diseaseEuropean Urology
researchProduct

The waiting time for prostate cancer treatment in Italy: analysis from the PROS-IT CNR Study.

2022

Background Prostate cancer (PCa) is the second most common neoplasm in male patients. To date, there's no certain indication about the maximum waiting time (WT) acceptable for treatment beginning and the impact on oncological and functional outcomes has not been well established. Methods Data from the National Research Council PCa monitoring multicenter project in Italy (Pros-IT CNR) were prospectively collected and analyzed. WT was defined as the time from the bioptical diagnosis of PCa to the first treatment received. Patients were divided in two groups, using a time frame of 90 days. Quality of life was measured through the Italian version of the University of California Los Angeles-Pros…

Waiting timeMalemedicine.medical_specialtyWaiting ListsUrologyLymph node metastasisAndrogen deprivation therapySettore MED/06Prostate cancerPercutaneous Coronary Interventionprostate cancer radical prostatectomy screeningQuality of lifeSettore MED/36Internal medicinemedicineHumansWaiting lists; Prostatic neoplasms; Prostatectomy; Radiotherapy; Androgens; Humans; Male; Prostate; Quality of Life; Waiting Lists; Percutaneous Coronary Intervention; Prostatic NeoplasmsProstatectomySurgical approachRadiotherapybusiness.industryscreeningProstateCancerProstatic NeoplasmsWaiting timeprostate cancermedicine.diseaseradical prostatectomyNephrologyAndrogensQuality of LifeT-stagePositive Surgical Marginbusiness
researchProduct